Source comparison
CJC-1295 no DAC vs DAC-Modified CJC-1295: Safety Comparison
The addition of Drug Affinity Complex (DAC) to CJC-1295 extends the peptide's half-life from 30 minutes to approximately 6–8 days by binding non-covalently to serum albumin. This pharmacokinetic modification fundamentally alters the cjc-1295 no dac safety prof
This comparison does not assign a generated winner or score.
- The addition of Drug Affinity Complex (DAC) to CJC-1295 extends the peptide's half-life from 30 minutes to approximately 6–8 days by binding non-covalently to serum albumin. This pharmacokinetic modification fundamentally alters the cjc-1295 no dac safety profile in ways that extend beyond simple dosing convenience.
- Half-life
- ~30 minutes
- ~6–8 days
- Short half-life limits cumulative exposure and preserves pulsatile GH secretion. DAC modification sacrifices physiological rhythm for convenience
- Dosing frequency
- 2–3× daily
- 1–2× weekly
- Frequent dosing with no-DAC maintains natural GH pulse architecture; weekly DAC dosing creates sustained elevation that may suppress endogenous GHRH tone
- GH secretion pattern
- Pulsatile (amplifies natural peaks)
- Sustained elevation (blunts circadian rhythm)
- Pulsatile secretion preserves negative feedback loops and insulin sensitivity; sustained elevation increases risk of insulin resistance and receptor desensitization
- Injection site reactions
- 15–30% per injection
- 8–12% per injection
- Higher per-injection incidence with no-DAC, but DAC's longer depot duration may increase total inflammatory burden over weekly intervals
- Antibody formation risk
- 5–8% (12+ weeks)
- 12–18% (12+ weeks)
- DAC moiety introduces additional immunogenic epitopes; higher antibody incidence but still predominantly non-neutralizing
- Insulin sensitivity impact
- No significant change vs baseline
- Mild transient reduction (5–10% HOMA-IR increase)
- Continuous GH elevation with DAC antagonizes insulin signaling; pulsatile no-DAC secretion spares glucose homeostasis
- The practical implication: CJC-1295 no DAC is the safer choice for research models where preserving natural metabolic rhythms and minimizing systemic GH exposure are priorities. The DAC-modified version offers dosing simplicity but sacrifices the pulsatile secretion pattern that underpins much of the no-DAC safety advantage.